These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 14749553)
1. Ganciclovir in solid organ transplant recipients: is there a role for clinical pharmacokinetic monitoring? Scott JC; Partovi N; Ensom MH Ther Drug Monit; 2004 Feb; 26(1):68-77. PubMed ID: 14749553 [TBL] [Abstract][Full Text] [Related]
2. Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Pediatric Solid-organ Transplant Recipients: A Prospective Pharmacokinetic Study. Peled O; Berkovitch M; Rom E; Bilavsky E; Bernfeld Y; Dorfman L; Pappo A; Ziv-Baran T; Brandriss N; Bar-Haim A; Amir J; Ashkenazi-Hoffnung L Pediatr Infect Dis J; 2017 Aug; 36(8):745-750. PubMed ID: 28383392 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of ganciclovir in pediatric renal transplant recipients. Zhang D; Lapeyraque AL; Popon M; Loirat C; Jacqz-Aigrain E Pediatr Nephrol; 2003 Sep; 18(9):943-8. PubMed ID: 12883977 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of ganciclovir in haematopoietic stem cell transplantation recipients with or without renal impairment. Asano-Mori Y; Kanda Y; Oshima K; Watanabe T; Shoda E; Motokura T; Kurokawa M; Chiba S J Antimicrob Chemother; 2006 May; 57(5):1004-7. PubMed ID: 16551692 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic assessment of oral ganciclovir in lung transplant recipients with cystic fibrosis. Snell GI; Kotsimbos TC; Levvey BJ; Skiba M; Rutherford DM; Kong DC; Williams TJ; Krum H J Antimicrob Chemother; 2000 Apr; 45(4):511-6. PubMed ID: 10747829 [TBL] [Abstract][Full Text] [Related]
6. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. McGavin JK; Goa KL Drugs; 2001; 61(8):1153-83. PubMed ID: 11465876 [TBL] [Abstract][Full Text] [Related]
8. Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipients. Wong DD; van Zuylen WJ; Craig ME; Rawlinson WD Rev Med Virol; 2019 Mar; 29(2):e2023. PubMed ID: 30556615 [TBL] [Abstract][Full Text] [Related]
9. Optimal sparse sampling for estimating ganciclovir/valganciclovir AUC in solid organ transplant patients using NONMEN. Padullés Caldés A; Colom H; Caldes A; Cerezo G; Torras J; Grinyó JM; Lloberas N Ther Drug Monit; 2014 Jun; 36(3):371-7. PubMed ID: 24305626 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic profile of ganciclovir after its oral administration and from its prodrug, valganciclovir, in solid organ transplant recipients. Wiltshire H; Hirankarn S; Farrell C; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Clin Pharmacokinet; 2005; 44(5):495-507. PubMed ID: 15871635 [TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of valganciclovir prophylaxis in paediatric and adult solid organ transplant recipients. Vezina HE; Brundage RC; Balfour HH Br J Clin Pharmacol; 2014 Aug; 78(2):343-52. PubMed ID: 24528138 [TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Wiltshire H; Paya CV; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Zuideveld KP; Transplantation; 2005 Jun; 79(11):1477-83. PubMed ID: 15940035 [TBL] [Abstract][Full Text] [Related]
14. Liquid chromatographic method for the determination of ganciclovir and/or acyclovir in human plasma using pulsed amperometric detection. Kishino S; Takekuma Y; Sugawara M; Shimamura T; Furukawa H; Todo S; Miyazaki K J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Nov; 780(2):289-94. PubMed ID: 12401354 [TBL] [Abstract][Full Text] [Related]
15. Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients. Fishman JA; Doran MT; Volpicelli SA; Cosimi AB; Flood JG; Rubin RH Transplantation; 2000 Feb; 69(3):389-94. PubMed ID: 10706048 [TBL] [Abstract][Full Text] [Related]
16. Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics. Filler G; Lampe D; von Bredow MA; Lappenberg-Pelzer M; Rocher S; Strehlau J; Ehrich JH Pediatr Nephrol; 1998 Jan; 12(1):6-9. PubMed ID: 9502557 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of oral valganciclovir solution and intravenous ganciclovir in pediatric renal and liver transplant recipients. Pescovitz MD; Ettenger RB; Strife CF; Sherbotie JR; Thomas SE; McDiarmid S; Bartosh S; Ives J; Bouw MR; Bucuvalas J Transpl Infect Dis; 2010 Jun; 12(3):195-203. PubMed ID: 20002356 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Pharmacodynamics, and Therapeutic Drug Monitoring of Valganciclovir and Ganciclovir in Transplantation. Franck B; Autmizguine J; Marquet P; Ovetchkine P; Woillard JB Clin Pharmacol Ther; 2022 Aug; 112(2):233-276. PubMed ID: 34596243 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of ganciclovir during continuous venovenous hemodiafiltration in critically ill patients. Horvatits T; Kitzberger R; Drolz A; Zauner C; Jäger W; Böhmdorfer M; Kraff S; Fritsch A; Thalhammer F; Fuhrmann V; Schenk P Antimicrob Agents Chemother; 2014; 58(1):94-101. PubMed ID: 24145543 [TBL] [Abstract][Full Text] [Related]